1. "2014"
Formats
  1. Journal Article (2603)
  2. Meeting Abstract (1417)
  3. Book Section (235)
  4. Conference Paper (23)
  5. Book Whole (16)
  6. Review (3)
Groups
  1. Department of Medicine (1584)
  2. GSK Faculty (1082)
  3. Surgery (895)
  4. Solid Tumor Oncology Division (840)
  5. Center for Hematologic Malignancies (703)
  6. Sloan Kettering Institute Faculty (672)

More Groups

People
  1. Jedd Wolchok (71)
  2. Sergio Giralt (71)
  3. Ross Levine (69)
  4. Martin Tallman (62)
  5. Michael Berger (59)
  6. Mithat Gonen (55)

More People

Years
  1. 2014 (4297)
Publications
  1. Journal of Clinical Oncology (420)
  2. Blood (228)
  3. International Journal of Radiation Oncology, Biology, Physics (131)
  4. Cancer Research (104)
  5. Modern Pathology (89)
  6. Laboratory Investigation (82)

More Publications

Publishers
  1. Elsevier Inc. (495)
  2. American Society of Clinical Oncology (446)
  3. Springer (318)
  4. Elsevier Science, Inc. (246)
  5. Nature Publishing Group (242)
  6. American Society of Hematology (230)

More Publishers

Results (4297)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Establishing a neoadjuvant platform for developing targeted agents: Degarelix prior to prostatectomy for patients with intermediate- and high-risk prostate cancer
    Meeting Abstract

    Touijer, K. A.; Carver, B. S.; Coleman, J. A.; Laudone, V. P.; Hullings, M.; Ehrlich, S. S.; DeNunzio, M.; Reuter, V. E.; Eastham, J. A.; Danila, D. C.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • A phase 2 trial of minocydine versus placebo to prevent neuropathy in patients (pts) with multiple myeloma (MM)
    Meeting Abstract

    Thomas, S. K.; Mendoza, T. R.; Dougherty, P. M.; Williams, L. A.; Wang, X. S.; Prasad, S.; Shah, N.; Shah, J. J.; Wang, M.; Weber, D. M.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • A randomized phase II trial of bevacizumab (BV) plus oral everolimus (EV) versus bevacizumab alone for recurrent or persistent epithelial ovarian (EOC), fallopian tube (FTC), or primary peritoneal cancer (PPC)
    Meeting Abstract

    Tew, W. P.; Sill, M.; McMeekin, D. S.; Secord, A. A.; Bonebrake, A. J.; Schilder, J.; Stuckey, A.; Rice, L.; Tewari, K. S.; Aghajanian, C.
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • APACT: A phase 3 randomized, open-label, multicenter trial evaluating the use of adjuvant nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone in patients (pts) with surgically resected ductal pancreatic adenocarcinoma (PDA)
    Meeting Abstract

    Tempero, M. A.; Cardin, D. B.; Biankin, A.; Goldstein, D.; Moore, M.; O'Reilly, E. M.; Philip, P. A.; Riess, H.; Macarulla, T.; Yung, L.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Early phase I study of the PARP inhibitor veliparib (ART-888) alone or in combination with carboplatia/paclitaxel (CP) in patients with varying degrees of hepatic or renal dysfunction: A study of the NCI-Organ Dysfunction Working Group (ODG)
    Meeting Abstract

    Tawbi, H. A. H.; Chu, E.; Lin, Y.; Hyman, D. M.; Goel, S.; Rudek, M. A.; Dowlati, A.; LoRusso, P.; Mulkerin, D.; Chew, H. K.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • A pilot study of PLX3397, a selective colony-stimulating factor 1 receptor (CSF1R) kinase inhibitor, in pigmented villonodular synovitis (PVNS)
    Meeting Abstract

    Tap, W. D.; Anthony, S. P.; Chmielowski, B.; Staddon, A. P.; Cohn, A. L.; Shapiro, G.; Puzanov, I.; Kwak, E. L.; Wagner, A. J.; Peterfy, C.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Ceritinib in Asian versus Caucasian patients (Pts) with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK plus ) NSCLC: Subgroup analysis of the ASCEND-1 trial
    Meeting Abstract

    Tan, D. S. W.; Shaw, A. T.; Mehra, R.; Felip, E.; Chow, L. Q. M.; Camidge, D. R.; Vansteenkiste, J. F.; Sharma, S.; De Pas, T.; Riely, G. J.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • VE-BASKET, a Simon 2-stage adaptive design, phase II, histology-independent study in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m): Activity of vemurafenib (VEM) with or without cetuximab (CTX) in. colorectal cancer (CRC)
    Meeting Abstract

    Tabernero, J.; Chan, E.; Baselga, J.; Blay, J. Y.; Chau, I.; Hyman, D. M.; Raje, N. S.; Wolf, J.; Sirzén, F.; Veronese, M. L.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL)
    Meeting Abstract

    Sznol, M.; Kluger, H. M.; Callahan, M. K.; Postow, M. A.; Gordon, R. A.; Segal, N. H.; Rizvi, N. A.; Lesokhin, A. M.; Atkins, M. B.; Kirkwood, J. M.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Preliminary findings from a phase I, multicenter, open-label study of the anti-CD37 antibody-drug conjugate (ADC), IMGN529, in adult patients with relapsed or refractory non-Hodgkin lymphoma (NHL)
    Meeting Abstract

    Stathis, A.; Maddocks, K. J.; Flinn, I.; Mejia, A.; Palomba, M. L.; Zildjian, S.; Murphy, M.; Deckert, J.; Ruiz-Soto, R.; Freedman, A.
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save